PRESCRIBE NOW!

The Different Cyclosporine


VEVYE® (cyclosporine ophthalmic solution) 0.1% is the first and only water-free cyclosporine dissolved in a semifluorinated alkane approved to treat both the signs and symptoms of dry eye disease.1-3

Shifting the paradigm in dry eye treatment with semifluorinated alkane technology.1

VEVYE (cyclosporine ophthalmic solution) 0.1% utilizes a novel water-free vehicle (perfluorobutylpentane), which allows VEVYE to spread evenly over the ocular surface with longer residual time and increased penetration of cyclosporine.1,4

The VEVYE Difference

Rapid Onset 5

  • 66% of subjects had 3 or more grades of tCFS (total corneal fluorescein staining) improvement by Day 29*
  • 57% of patients showed at least 3 grades of improvement in tCFS at Day 15*
  • Provided sustained improvement over 12 months†

HIGH PATIENT tolerability 5

  • 99.8% of patients experienced no or mild site instillation irritation*
  • In a 52-week extension study (n=202), only 1 patient discontinued treatment due to an ocular adverse event (mild burning/stinging)†
  • Blood concentrations of cyclosporine were below the measurable amount

water-free 1

  • Preservative-free
  • No pH or osmolarity

low surface tension 5-6

  • VEVYE's low surface tension improves the lipid layer grading immediately after administration
  • Perfluorobutylpentane remains in tears for up to 8 hours
  • *In pooled clinical studies
  • **A phase 3, prospective, multicenter, open-label study
  • †An open-label, single-arm safety study

To learn more about VEVYE:

CONNECT WITH A
REPRESENTATIVE
INDICATION AND USAGE: VEVYE® (cyclosporine ophthalmic solution) 0.1% is indicated for the treatment of the signs and symptoms of dry eye disease.
IMPORTANT SAFETY INFORMATION
Warnings and Precautions
Potential for Eye Injury and Contamination – To avoid the potential for eye injury and/or contamination, patients should not touch the bottle tip to the eye or other surfaces.
Use with Contact Lenses – VEVYE should not be administered while wearing contact lenses. If contact lenses are worn, they should be removed prior to administration of the solution. Lenses may be reinserted 15 minutes following the administration of VEVYE.
Adverse Reactions
In clinical trials with 738 subjects receiving at least 1 dose of VEVYE, the most common adverse reactions were instillation site reactions (8%) and temporary decreases in visual acuity (3%).
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.
For additional information about VEVYE, please see the Full Prescribing Information.
References: 1. Vevye (cyclosporine ophthalmic solution) 0.1% [package insert]. Harrow IP, LLC; 2023. 2. Restasis (cyclosporine ophthalmic emulsion) 0.05% [package insert]. Allergan, LLC; 2023. 3. Cequa (cyclosporine ophthalmic solution) .09% [package insert]. Sun Ophthalmics, LLC; 2023. 4. Agarwal P, Korward J, Krösser S, Rupenthal ID. Preclinical characterization of water-free cyclosporine eye drops - Factors impacting ocular penetration ex vivo and in vivo. Eur J Pharm Biopharm. 2023 Jul;188:100-107. doi: 10.1016/j.ejpb.2023.05.005. Epub 2023 May 11. PMID: 37178940. 5. Data on file. 6. P. Agarwal, D. Khun, S. Kr¨osser, K. Eickhoff, F.S. Wells, G.R. Willmott, et al., Preclinical studies evaluating the effect of semifluorinated alkanes on ocular surface and tear fluid dynamics, Ocul Surf. 17 (2019) 241–249, https://doi.org/ 10.1016/j.jtos.2019.02.010. 7. Agarwal P, Scherer D, Günther B, Rupenthal ID. Semifluorinated alkane based systems for enhanced corneal penetration of poorly soluble drugs. Int J Pharm. 2018 Mar 1;538(1-2):119-129. doi: 10.1016/j.ijpharm.2018.01.019. Epub 2018 Jan 12. PMID: 29339249.

ARE YOU A PATIENT
OR A HEALTHCARE PROFESSIONAL?

Patient
Healthcare Professional

ARE YOU A PATIENT
OR A US HEALTHCARE PROFESSIONAL?

Patient
US Healthcare Professional